Advanced glycation end products and diabetic foot disease

Diabetes/Metabolism Research and Reviews

Volumn 24, Issue SUPPL. 1, 2008, Pages

  Huijberts, Maya S P ^a   Schaper, Nicolaas C ^a   Schalkwijk, Casper G ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Advanced glycation end products; Atherosclerosis; Diabetic foot disease; Neuropathy; Wound healing

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ACETYLSALICYLIC ACID; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALAGEBRIUM; AMINOGUANIDINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BENFOTIAMINE; COLLAGEN TYPE 4; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLAVONOID; IBUPROFEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOMETACIN; INTERLEUKIN 6; LAMININ; LOW DENSITY LIPOPROTEIN; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE 3; NITRIC OXIDE; PENTOSIDINE; PHOSPHATIDYLINOSITOL 3 KINASE; PYRIDOXAMINE; SYNAPTOTAGMIN I; THIAMINE;

ANTIOXIDANT ACTIVITY; ARTERY DISEASE; ATHEROSCLEROSIS; CARBOHYDRATE ANALYSIS; CLINICAL TRIAL; CONFERENCE PAPER; DIABETES MELLITUS; DIABETIC FOOT; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE PREDISPOSITION; GENE EXPRESSION; GLYCATION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERGLYCEMIA; LIGAND BINDING; LIPID PEROXIDATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RECEPTOR BINDING; RISK FACTOR; SIGNAL TRANSDUCTION; TISSUE INJURY; UNSPECIFIED SIDE EFFECT; UPREGULATION; VASCULAR DISEASE; WOUND HEALING; WOUND HEALING IMPAIRMENT;

ATHEROSCLEROSIS; DIABETIC FOOT; DIABETIC NEUROPATHIES; DISEASE PROGRESSION; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; RECEPTORS, IMMUNOLOGIC; WOUND HEALING;

EID: 44949231447     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.861     Document Type: Conference Paper

References (65)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
3. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005; 54: 1615-1625.
4. Boulton AJ, Vileikyte L, Ragnarson-Tennvall G, Apelqvist J. The global burden of diabetic foot disease. Lancet 2005; 366: 1719-1724.
5. Jeffcoate W, Bakker K. World diabetes day: footing the bill. Lancet 2005; 365: 1527.
6. Koschinsky T, He CJ, Mitsuhashi T, et al. Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci U S A 1997; 94: 6474-6479.
7. Giardino I, Edelstein D, Brownlee M. BCL-2 expression or antioxidants prevent hyperglycemia-induced formation of intracellular advanced glycation endproducts in bovine endothelial cells. J Clin Invest 1996; 97: 1422-1428.
8. Giardino I, Edelstein D, Brownlee M. Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity. A model for intracellular glycosylation in diabetes. J Clin Invest 1994; 94: 110-117.
9. Ruderman NB, Williamson JR, Brownlee M. Glucose and diabetic vascular disease. FASEB J 1992; 6: 2905-2914.
10. Schalkwijk CG, Stehouwer CD, van Hinsbergh VW. Fructose-mediated non-enzymatic glycation: sweet coupling or bad modification. Diabetes Metab Res Rev 2004; 20: 369-382.
11. Westwood ME, Thornalley PJ. Molecular characteristics of methylglyoxal-modified bovine and human serum albumins. Comparison with glucose-derived advanced glycation endproduct-modified serum albumins. J Protein Chem 1995; 14: 359-372.
12. Phillips SA, Thornalley PJ. Formation of methylglyoxal and D-lactate in human red blood cells in vitro. Biochem Soc Trans 1993; 21: 163S.
13. Shinohara M, Thornalley PJ, Giardino I, et al. Overexpression of glyoxalase-I in bovine endothelial cells inhibits intracellular advanced glycation endproduct formation and prevents hyperglycemia-induced increases in macromolecular endocytosis. J Clin Invest 1998; 101: 1142-1147.
14. Monnier VM, Stevens VJ, Cerami A. Maillard reactions involving proteins and carbohydrates in vivo: relevance to diabetes mellitus and aging. Prog Food Nutr Sci 1981; 5: 315-327.
15. Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: a review. Diabetologia 2001; 44: 129-146.
16. Thornalley PJ. Glycation in diabetic neuropathy: characteristics, consequences, causes, and therapeutic options. Int Rev Neurobiol 2002; 50: 37-57.
17. Ahmed N. Advanced glycation endproducts-role in pathology of diabetic complications. Diabetes Res Clin Pract 2005; 67: 3-21.
18. Smit AJ, Lutgers HL. The clinical relevance of advanced glycation endproducts (AGE) and recent developments in pharmaceutics to reduce AGE accumulation. Curr Med Chem 2004; 11: 2767-2784.
19. Basta G, Lazzerini G, Massaro M, et al. Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation 2002; 105: 816-822.
20. Stitt AW, Bucala R, Vlassara H. Atherogenesis and advanced glycation: promotion, progression, and prevention. Ann N Y Acad Sci 1997; 811: 115-127, discussion 127-9.
21. Vlassara H. Advanced glycation end-products and atherosclerosis. Ann Med 1996; 28: 419-426.
22. Makita Z, Yanagisawa K, Kuwajima S, Bucala R, Vlassara. H, Koike T. The role of advanced glycosylation end-products in the pathogenesis of atherosclerosis. Nephrol Dial Transplant 1996; 11(Suppl. 5): 31-33.
23. Lue LF, Walker DG, Brachova L, et al. Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: identification of a cellular activation mechanism. Exp Neurol 2001; 171: 29-45.
24. Yan SD, Schmidt AM, Stern D. Alzheimer's disease: inside, outside, upside down. Biochem Soc Symp 2001; 15-22.
25. Stern DM, Yan SD, Yan SF, Schmidt AM. Receptor for advanced glycation endproducts (RAGE) and the complications of diabetes. Ageing Res Rev 2002; 1: 1-15.
26. Miyazaki A, Nakayama H, Horiuchi S. Scavenger receptors that recognize advanced glycation end products. Trends Cardiovasc Med 2002; 12: 258-262.
27. Schmidt AM, Hori O, Cao R, et al. RAGE: a novel cellular receptor for advanced glycation end products. Diabetes 1996; 45(Suppl. 3): S77-S80.
28. Bierhaus A, Humpert PM, Morcos M, et al. Understanding RAGE, the receptor for advanced glycation end products. J Mol Med 2005; 83: 876-886.
29. Bierhaus A, Schiekofer S, Schwaninger M, et al. Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes 2001; 50: 2792-2808.
30. Ishihara K, Tsutsumi K, Kawane S, Nakajima M, Kasaoka T. The receptor for advanced glycation end-products (RAGE) directly binds to ERK by a D-domain-like docking site. FEBS Lett 2003; 550: 107-113.
31. Lander HM, Tauras JM, Ogiste JS, Hori O, Moss RA, Schmidt AM. Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J Biol Chem 1997;272: 17810-17814.
32. Prompers I., Huijberts M, Apelqvist J, et al. High prevalence of ischaemia, infection and serious comorbidity in patients with diabetic foot disease in Europe. Baseline results from the Eurodiale study. Diabetologia 2007; 50: 18-25.
33. Brownlee M, Vlassara H, Cerami A. Trapped immunoglobulins on peripheral nerve myelin from patients with diabetes mellitus. Diabetes 1986; 35(9): 999-1003.
34. Cameron NE, Cotter MA, Dines KC, Maxfield EK, Carey F, Mirrlees DJ. Aldose reductase inhibition, nerve perfusion, oxygenation and function in streptozotocin-diabetic rats: dose-response considerations and independence from a myo-inositol mechanism. Diabetologia 1994; 37: 651-663.
35. Cameron NE, Cotter MA, Archibald V, Dines KC, Maxfield EK. Anti-oxidant and pro-oxidant effects on nerve conduction velocity, endoneurial blood flow and oxygen tension in non-diabetic and streptozotocin-diabetic rats. Diabetologia 1994; 37: 449-459.
36. Vincent AM, Perrone L, Sullivan KA, et al. Receptor for advanced glycation end products activation injures primary sensory neurons via oxidative stress. Endocrinology 2007; 148: 548-558.
37. Rong LL, Gooch C, Szabolcs M, et al. RAGE: a journey from the complications of diabetes to disorders of the nervous system - striking a fine balance between injury and repair. Restor Neurol Neurosci 2005; 23: 355-365.
38. Rong LL, Yan SF, Wendt T, et al. RAGE modulates peripheral nerve regeneration via recruitment of both inflammatory and axonal outgrowth pathways. FASEB J 2004; 18: 1818-1825.
39. Ozturk G, Sekeroglu MR, Erdogan E, Ozturk M. The effect of non-enzymatic glycation of extracellular matrix proteins on axonal regeneration in vitro. Acta Neuropathol (Berl) 2006; 112: 627-632.
40. Bierhaus A, Haslbeck KM, Humpert PM, et al. Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily. J Clin Invest 2004; 114: 1741-1751.
41. Misur I, Zarkovic K, Barada A, Batelja L, Milicevic Z, Turk Z. Advanced glycation endproducts in peripheral nerve in type 2 diabetes with neuropathy. Acta Diabetol 2004; 41(4): 158-166.
42. Meerwaldt R, Links TP, Graaff R, et al. Increased accumulation of skin advanced glycation end-products precedes and correlates with clinical manifestation of diabetic neuropathy. Diabetologia 2005; 48: 1637-1644.
43. Jeffcoate WJ, Chipchase SY, Ince P, Game FL. Assessing the outcome of the management of diabetic foot ulcers using ulcer-related and person-related measures. Diabetes Care 2006; 29: 1784-1787.
44. Lopes-Virella MF, Klein RL, Lyons TJ, Stevenson HC, Witztum JL. Glycosylation of low-density lipoprotein enhances cholesteryl ester synthesis in human monocyte-derived macrophages. Diabetes 1988; 37: 550-557.
45. Wendt T, Harja E, Bucciarelli L, et al. RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes. Atherosclerosis 2006; 185(1): 70-77.
46. Bucciarelli LG, Wendt T, Qu W, et al. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 2002; 106: 2827-2835.
47. Baidoshvili A, Krijnen PA, Kupreishvili K, et al. N(varepsilon)- (carboxymethyl)lysine depositions in intramyocardial blood vessels in human and rat acute myocardial infarction: a predictor or reflection of infarction? Arterioscler Thromb Vasc Biol 2006; 26: 2497-2503.
48. Lutgers HL, Graaff R, Links TP, et al. Skin autofluorescence as a noninvasive marker of vascular damage in patients with type 2 diabetes. Diabetes Care 2006; 29: 2654-2659.
49. Lapolla A, Piarulli F, Sartore G, et al. Advanced glycation end products and antioxidant status in type 2 diabetic patients with and without peripheral artery disease. Diabetes Care 2007; 30: 670-676.
50. Peppa M, Brem H, Ehrlich P, et al. Adverse effects of dietary glycotoxins on wound healing in genetically diabetic mice. Diabetes 2003; 52: 2805-2813.
51. Goova MT, Li J, Kislinger T, et al. Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice. Am J Pathol 2001; 159: 513-525.
52. Monnier VM. Intervention against the Maillard reaction in vivo. Arch Biochem Biophys 2003; 419: 1-15.
53. Thornalley PJ. Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts. Arch Biochem Biophys 2003; 419: 31-40.
54. Freedman BI, Wuerth JP, Cartwright K, et al. Design and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II). Control Clin Trials 1999; 20: 493-510.
55. Bolton WK, Cattran DC, Williams ME, et al. Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol 2004; 24: 32-40.
56. Beisswenger P, Ruggiero-Lopez D. Metformin inhibition of glycation processes. Diabetes Metab 2003; 29(4 Pt 2): 6S95-6103.
57. Voziyan PA, Hudson BG. Pyridoxamine: the many virtues of a maillard reaction inhibitor. Ann N Y Acad Sci 2005; 1043: 807-816.
58. Voziyan PA, Hudson BG. Pyridoxamine as a multifunctional pharmaceutical: targeting pathogenic glycation and oxidative damage. Cell Mol Life Sci 2005; 62: 1671-1681.
59. Susic D, Varagic J, Ahn J, Frohlich ED. Crosslink breakers: a new approach to cardiovascular therapy. Curr Opin Cardiol 2004; 19: 336-340.
60. Susic D, Varagic J, Ahn J, Frohlich ED. Collagen cross-link breakers: a beginning of a new era in the treatment of cardiovascular changes associated with aging, diabetes, and hypertension. Curr Drug Targets Cardiovasc Haematol Disord 2004; 4: 97-101.
61. Kass DA, Shapiro EP, Kawaguchi M, et al. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation 2001; 104: 1464-1470.
62. Little WC, Zile MR, Kitzman DW, Hundley WG, O'Brien TX, Degroof RC. The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. J Card Fail 2005; 11: 191-195.
63. Bakris GL, Bank AJ, Kass DA, Neutel JM, Preston RA, Oparil S. Advanced glycation end-product cross-link breakers. A novel approach to cardiovascular pathologies related to the aging process. Am J Hypertens 2004; 17(12 Pt 2): 23S-30S.
64. Zieman SJ, Melenovsky V, Clattenburg L, et al. Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension. J Hypertens 2007; 25: 577-583.
65. Forbes JM, Thomas MC, Thorpe SR, Alderson NL, Cooper ME. The effects of valsartan on the accumulation of circulating and renal advanced glycation end products in experimental diabetes. Kidney Int Suppl 2004; (92): S105-S107.